High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment

This publication has 14 references indexed in Scilit:

• Treatment of Breast Cancer
  New England Journal of Medicine, 1998
• Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
  Journal of Clinical Oncology, 1998
• Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects
  European Journal Of Cancer, 1996
• Aromatase inhibitors
  Endocrine-Related Cancer, 1996
• Novel aromatase and 5α-reductase inhibitors
  The Journal of Steroid Biochemistry and Molecular Biology, 1994
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
  The Lancet, 1992
• Novel Irreversible Aromatase Inhibitors
  Annals of the New York Academy of Sciences, 1990
• Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association.
  Journal of Clinical Oncology, 1988
• Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo
  Steroids, 1981
• Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
  BMJ, 1981